An Investigation of Sleep Architecture in Ziprasidone-Treated Bipolar Depression

NCT00835107

Last updated date
Study Location
Providence Care Mental Health Services
Kingston, Ontario, K7L 4X3, Canada
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Bipolar Depression
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- A diagnosis of Bipolar Disorder Type 1,2 or NOS by Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition (DSM-IV).

- Current depressive episode with a HAMD-17 of >16.

- Males or Females over age 18yrs.

- Inpatients or outpatients.

- Female patients of childbearing potential must be using a reliable method of contraception and have a negative urine human chorionic gonadotropin (HCG) test at enrolment.

- Able to understand and comply with the requirements of the study.

- Provision of written informed consent.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Current Manic, Hypomanic or Mixed episode, with YMRS > 12.


- Current or past diagnosis of Schizophrenia and Dementia.


- Pregnant women, or women in childbearing age, not willing to use appropriate
contraception or women currently nursing.


- Patient on any other antipsychotic medication.


- Patients who, in the opinion of the investigator, pose an imminent risk of suicide or
a danger to self or others.


- Known intolerance or lack of response to Ziprasidone, as judged by the investigator.


- Benzodiazepines and all other sleep-aids must be discontinued prior to participation
in the study if they have not been at a stable dosage for the 4 weeks previous to
entry into the study.


- No change to the current medication regime (excluding discontinuation of sleep aids
and antipsychotic medications) is allowed 4 weeks prior to the first PSG reading.


- Administration of a depot antipsychotic injection within two dosing interval (for the
depot) before randomization.


- Substance or alcohol dependence at enrolment or in the last three months (except for
caffeine or nicotine dependence), as defined by DSM-IV criteria.


- Serious, unstable or inadequately treated medical illness as judged by the
investigator.


- History of epilepsy or uncontrolled seizures.


- Involvement in the planning and conduct of the study.


- Previous enrolment in the present study.


- Participation in another drug trial within 4 weeks prior enrolment into this study or
longer in accordance with local requirements.


- Patients with serum potassium, magnesium and/or calcium levels outside the normal
range at baseline.


- Patients with marked liver function abnormalities at baseline, demonstrated by
laboratory values, by judgment of the investigator.


- Known serological evidence of HIV, or acute or chronic hepatitis; donation of blood or
blood products for transfusion prior to initiation of the treatment with study drug,
during the study and for 30 days after the study has ended.


- Known history of QT prolongation (including congenital long QT syndrome).


- Recent acute myocardial infarction or uncompensated heart failure.


- Currently taking other drugs that are known to prolong the QT interval.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Bipolar DepressionAn Investigation of Sleep Architecture in Ziprasidone-Treated Bipolar Depression
NCT00835107
  1. Kingston, Ontario
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE An Investigation of Sleep Architecture in Ziprasidone-Treated Bipolar Depression
Official Title  ICMJE An Investigation of Sleep Architecture in Ziprasidone-Treated Bipolar Depression
Brief Summary This study uses polysomnographs(PSG) to investigate sleep patterns in patients with bipolar depression. This is a double-blind, placebo-controlled, study of ziprasidone that is added to patients current medications. The objective is to relate changes in slow wave and rapid eye movement sleep to changes in mood and overall illness severity. Participants will be randomly assigned to add either placebo or ziprasidone to their current treatment regimen. Participants make 3 to 4 study visits, over a 1 month period, at which they will be asked about their history, mood and sleep quality. Participants will also have three in-home overnight polysomnographs.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Depression, Bipolar
Intervention  ICMJE
  • Drug: ziprasidone hydrochloride
    oral capsules, from 40-80 mg BID, for one month with the option to continue the medication after the study has been completed
    Other Name: Zeldox
  • Drug: placebo
    placebo comparator, oral capsules, BID, for one month
Study Arms  ICMJE
  • Experimental: Ziprasidone
    Intervention: Drug: ziprasidone hydrochloride
  • Placebo Comparator: Sugar pill
    Intervention: Drug: placebo
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: November 21, 2011)
14
Original Estimated Enrollment  ICMJE
 (submitted: February 2, 2009)
32
Actual Study Completion Date  ICMJE June 2011
Actual Primary Completion Date June 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • A diagnosis of Bipolar Disorder Type 1,2 or NOS by Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition (DSM-IV).
  • Current depressive episode with a HAMD-17 of >16.
  • Males or Females over age 18yrs.
  • Inpatients or outpatients.
  • Female patients of childbearing potential must be using a reliable method of contraception and have a negative urine human chorionic gonadotropin (HCG) test at enrolment.
  • Able to understand and comply with the requirements of the study.
  • Provision of written informed consent.

Exclusion Criteria:

  • Current Manic, Hypomanic or Mixed episode, with YMRS > 12.
  • Current or past diagnosis of Schizophrenia and Dementia.
  • Pregnant women, or women in childbearing age, not willing to use appropriate contraception or women currently nursing.
  • Patient on any other antipsychotic medication.
  • Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others.
  • Known intolerance or lack of response to Ziprasidone, as judged by the investigator.
  • Benzodiazepines and all other sleep-aids must be discontinued prior to participation in the study if they have not been at a stable dosage for the 4 weeks previous to entry into the study.
  • No change to the current medication regime (excluding discontinuation of sleep aids and antipsychotic medications) is allowed 4 weeks prior to the first PSG reading.
  • Administration of a depot antipsychotic injection within two dosing interval (for the depot) before randomization.
  • Substance or alcohol dependence at enrolment or in the last three months (except for caffeine or nicotine dependence), as defined by DSM-IV criteria.
  • Serious, unstable or inadequately treated medical illness as judged by the investigator.
  • History of epilepsy or uncontrolled seizures.
  • Involvement in the planning and conduct of the study.
  • Previous enrolment in the present study.
  • Participation in another drug trial within 4 weeks prior enrolment into this study or longer in accordance with local requirements.
  • Patients with serum potassium, magnesium and/or calcium levels outside the normal range at baseline.
  • Patients with marked liver function abnormalities at baseline, demonstrated by laboratory values, by judgment of the investigator.
  • Known serological evidence of HIV, or acute or chronic hepatitis; donation of blood or blood products for transfusion prior to initiation of the treatment with study drug, during the study and for 30 days after the study has ended.
  • Known history of QT prolongation (including congenital long QT syndrome).
  • Recent acute myocardial infarction or uncompensated heart failure.
  • Currently taking other drugs that are known to prolong the QT interval.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00835107
Other Study ID Numbers  ICMJE PSIY-287-08
GA128250
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Dr. Roumen Milev, Queen's University
Study Sponsor  ICMJE Queen's University
Collaborators  ICMJE
  • Providence Health & Services
  • Pfizer
  • MDS Pharma Services
Investigators  ICMJE
Principal Investigator:Roumen Milev, MDQueen's University
Principal Investigator:Anusha Baskaran, BScHQueen's University
PRS Account Queen's University
Verification Date December 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP